Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Shares of Agios Pharmaceuticals (AGIO) rose more than 20% on Monday after management reported that the phase III ENERGIZE-T study, evaluating its sole marketed drug, Pyrukynd (mitapivat) in certain thalassemia patients, achieved its primary and key secondary endpoints. Image Source: Zacks Investment Research A total of 258 adult participants with transfusion-dependent (TD) alpha- or beta-thalassemia were enrolled in the ENERGIZE-T study. These patients were randomized into two treatment arms — 171 patients ...